Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2024-08-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药第二届董事会第九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Guobang Pharmaceutical Group Co., Ltd. It details the convening and decisions of the company's second board's ninth meeting held on August 29, 2024. The key agenda items include approval of the 2024 semi-annual report and its summary, and approval of a special report on the use of raised funds for the half-year period. The document references the actual reports being disclosed on the Shanghai Stock Exchange website, indicating this document itself is not the report but an announcement of board resolutions related to those reports. The document length is short (792 characters), and it primarily serves as a formal announcement of board decisions rather than containing substantive financial data or the reports themselves. Therefore, it fits best under the category of Board/Management Information (MANG), as it announces board meeting resolutions and approvals.
2024-08-29 Chinese
国邦医药2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report". It covers the period from January 1, 2024 to June 30, 2024, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as revenue, net profit, cash flow, and financial indicators, as well as management discussion and analysis, company overview, business operations, and risk disclosures. The length is substantial (15,000 characters) and contains actual financial statements and substantive analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR).
2024-08-29 Chinese
国邦医药关于股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement by Guobang Pharmaceutical Group Co., Ltd. regarding a shareholder's plan to reduce their shareholding. It details the shareholders involved, the number and percentage of shares to be reduced, the methods of reduction (centralized bidding and block trading), the timing, and the reasons for the reduction. The document includes risk warnings and compliance with relevant securities laws and regulations. There is no financial data, earnings information, or management discussion. The content is focused on the shareholder's intention and plan to sell shares, which fits the definition of a Major Shareholding Notification (MRQ) as it involves notification of changes in significant share ownership levels. The document length is 3252 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2024-08-26 Chinese
国邦医药关于股东减持股份计划期限届满暨减持结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholder's share reduction plan, detailing the number of shares held before and after the reduction, the reduction period, methods, and prices. It includes specific shareholder names, shareholding percentages, and confirms that the reduction plan was implemented as planned. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of shareholding changes by significant shareholders, fitting the definition of a Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2024-08-15 Chinese
国邦医药关于第一期员工持股计划完成非交易过户暨购买完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a company's employee stock ownership plan, including details about stock transfers, purchase amounts, and lock-up periods. It is a formal disclosure about share transactions related to the company's employee stock plan, not a financial report or earnings release. The content fits the category of a Transaction in Own Shares (POS), as it reports on the company's repurchase and allocation of its own shares to employees.
2024-08-06 Chinese
国邦医药第一期员工持股计划第一次持有人会议决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the first meeting of holders of the company's first employee stock ownership plan. It details the establishment of a management committee, election of committee members, and authorization of the committee to manage the plan. There is no financial data, no report attached or referenced as published, and no indication of a full report or regulatory filing. The content is about decisions and governance related to the employee stock ownership plan, which is a shareholder-related announcement. This fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like capital changes or director dealings.
2024-08-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.